Standout Papers
Citation Impact
Citing Papers
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
2012
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
2018 StandoutNobel
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
2018
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
2015
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
2016
Strategy for Dual-Analyte Luciferin Imaging: In Vivo Bioluminescence Detection of Hydrogen Peroxide and Caspase Activity in a Murine Model of Acute Inflammation
2013 StandoutNobel
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
2016
Engineering precision nanoparticles for drug delivery
2020 Standout
Ischemia and reperfusion—from mechanism to translation
2011 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
2016
Necroptosis and its role in inflammation
2015 StandoutNature
Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts
2011
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Combining immunotherapy and targeted therapies in cancer treatment
2012
Nucleotide signalling during inflammation
2014 StandoutNature
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
2017 StandoutNobel
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
2015
The biology and management of non-small cell lung cancer
2018 StandoutNature
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
2007 StandoutNobel
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
2014
Immuno-Oncology: Emerging Targets and Combination Therapies
2018
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response
2013
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Emerging Functions of Regulatory T Cells in Tissue Homeostasis
2018
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
2013
Nanoparticles for dendritic cell-based immunotherapy
2018
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
2015
Macrophages in Tissue Repair, Regeneration, and Fibrosis
2016 Standout
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
2015
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Macrophages and cancer: from mechanisms to therapeutic implications
2015
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
2014
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
2014
Immune checkpoint modulation: Rational design of combination strategies
2015
Krüppel-like Factor 4 Is Acetylated by p300 and Regulates Gene Transcription via Modulation of Histone Acetylation
2007
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Targeting T Cell Immunometabolism for Cancer Immunotherapy; Understanding the Impact of the Tumor Microenvironment
2014
Sickle-cell disease
2010 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Combination cancer immunotherapies tailored to the tumour microenvironment
2015
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
The secret ally: immunostimulation by anticancer drugs
2012
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Antigen-presenting cell function in the tolerogenic liver environment
2010
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
2012
Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy
2018
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Hepatocyte-Specific High-Mobility Group Box 1 Deletion Worsens the Injury in Liver Ischemia/Reperfusion: A Role for Intracellular High-Mobility Group Box 1 in Cellular Protection
2013
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Role of indoleamine 2,3-dioxygenase in health and disease
2015
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
2015
Regulatory T Cells and Human Disease
2020 StandoutNobel
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
2014
Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis
2012
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway
2014
Discovery of IDO1 Inhibitors: From Bench to Bedside
2017
Innate Immune Recognition of Cancer
2015
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Cellular Constituents of Immune Escape within the Tumor Microenvironment
2012
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
2019 Standout
Spermidine in health and disease
2018 StandoutScience
The interaction of anticancer therapies with tumor-associated macrophages
2015
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The Janus-Faced Nature of Ido1 in Infectious Diseases: Challenges and Therapeutic Opportunities
2015
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
2013
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
2012
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Characterization of Human Antiviral Adaptive Immune Responses during Hepatotropic Virus Infection in HLA-Transgenic Human Immune System Mice
2013 StandoutNobel
Cutting Edge: Chronic Inflammatory Liver Disease in Mice Expressing a CD28-Specific Ligand
2012 StandoutNobel
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart
2013 StandoutNobel
Tryptophan‐2,3‐dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor‐4
2015
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning
2012 StandoutNobel
Works of Lee M. Ocuin being referenced
KIT oncogene inhibition drives intratumoral macrophage M2 polarization
2013
Toll-Like Receptor 9 Inhibition Confers Protection From Liver Ischemia–Reperfusion Injury
2009
Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretion
2010
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Convergence of the thyroid hormone and gut-enriched Krüppel-like factor pathways in the context of enterocyte differentiation
2003